Anbio Biotechnology

NNNNNasdaq Germany Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances

Market cap

$1.527 B

$10.61 +8.82%

Close of 7 Aug 2026

Revenue

$8.65M

#3202 by revenue

Earnings

$6.40M

#2145 by earnings

Shares outstanding

43,672,022

Latest filing cover page

P/E ratio

238.4

Cap ÷ net income

Biotechnology: In Vitro & In Vivo Diagnostic Substances — ranked by market cap

All 19 →

#5NeogenNEOG$2.50B
#6Intellia TherapeuticsNTLA$1.67B
#7Anbio BiotechnologyNNNN$1.53B
#8QuidelOrthoQDEL$837.7M
#9Achieve Life SciencesACHV$682.7M

Where these numbers come from

Share counts and financials for Anbio Biotechnology are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.